Jaguar Animal Health Announces Positive Preliminary Topline Results of Two Chinese-sponsored Farm Studies to Evaluate the Safety and Effectiveness of Neonorm Botanical Extract in Piglets
The initial study, which took place from March to May of 2016, was a multi-site study, involving 433 piglets, from two age groups (1-3 days and 10-15 days), that had a history of diarrhea. The piglets were either placed in a treatment group in which they were individually treated with 10-20 mg of Neonorm™ powder in a water formulation twice daily for three days or placed in a control group.
In the groups of piglets aged 1-3 days, 99% achieved resolution of diarrhea following Neonorm™ treatment versus no resolution in the control group. There was a 3% mortality in the Neonorm™ group, while the control group had 100% mortality. In the group of piglets aged 10-15 days, the rate of diarrhea resolution was 70%, versus no resolution in the control group; mortality was 30% versus 100%, respectively. Comparisons of diarrhea resolution and mortality rates between the Neonorm™-treated group and control groups generated p-values less than 0.01.
The second study was initiated in June of this year at a farm in
The results of the second study demonstrate a 95% cure rate among piglets in group A, who received 10-20 mg of Neonorm™ administered over two days. The cure rate in group B among piglets that received 8-16 mg of Neonorm™ for three days was 60%. At this farm, a mortality rate of 50% is typically seen in piglets diagnosed with PEDv. Group C was treated prophylactically with 8-16 mg of Neonorm™ for three days and 15% developed diarrheal symptoms, which is similar to the usual frequency at this farm without prophylactic treatment.
"We are very encouraged by these preliminary results. As the most common disease in newborn pigs1, diarrhea has a significant impact on the global swine market as well as food security," stated
Jaguar has entered into negotiations for a potential exclusive distribution relationship for pigs and dairy cattle in the Chinese marketplace with the
According to the
PED can lead to significant economic loss in the swine industry because of the high morbidity and mortality that occurs in immunologically naïve neonatal piglets, according to the USDA. Vaccination and increased biosecurity needs related to PED further increase production costs2, and, per the USDA, there is currently no effective treatment against PED other than control of secondary infections.
According to the
Neonorm™ is a standardized botanical extract derived from the Croton lechleri tree, which is sustainably harvested. Neonorm™ Calf and Neonorm™ Foal are the Company's lead non-prescription products. Jaguar intends to develop species-specific formulations of Neonorm™ in six additional target species.
For more information, please visit www.jaguaranimalhealth.com.
Certain statements in this press release constitute "forward-looking statements." These include statements regarding a potential exclusive distribution relationship for pigs and dairy cattle in the Chinese marketplace between Jaguar and the
1Diarrhoea or Scour. Retrieved
2Song, D., Park, B., 2012. Porcine epidemic diarrhoea virus: a comprehensive review of molecular epidemiology, diagnosis, and vaccines. Virus genes 44, 167-175.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/jaguar-animal-health-announces-positive-preliminary-topline-results-of-two-chinese-sponsored-farm-studies-to-evaluate-the-safety-and-effectiveness-of-neonorm-botanical-extract-in-piglets-300303118.html
Garth Russell, KCSA Strategic Communications, P: 212-896-1250, firstname.lastname@example.org